CytoMed Therapeutics (GDTC) H1 2025 earnings summary

Executive summary

• Revenue for the six months ended 30 June 2025 increased by 100% to SGD 156,000, driven by new private blood banking services in Malaysia and asset acquisition.

• Net loss widened to SGD 2.25 million for the period, compared to SGD 1.09 million in the first half of 2024, due to higher research, share-based payments, and other expenses.

• Adjusted net loss, excluding share-based payments, currency exchange losses, warrant liability fair value losses, and public company costs, was SGD 1.44 million.

• Clinical-stage biopharma focused on allogeneic, off-the-shelf cell-based immunotherapies for cancer and degenerative diseases, with four product candidates in development and recent expansion into cord blood banking services.

• Phase 1 trial for lead candidate CTM-N2D underway; asset acquisition in Malaysia enabled first revenue from private blood banking.

Financial highlights

• Revenue for six months ended June 30, 2025 was SGD 155,887, primarily from private blood banking services.

• Other operating income decreased by 8.5% year-over-year, mainly due to lower interest income.

• Net loss widened to SGD 2.25 million, driven by higher research, share-based payments, and other expenses.

• Cash and bank balances declined to SGD 2.86 million as of 30 June 2025, down from SGD 4.97 million at 31 December 2024.

• Operating cash outflow increased to SGD 1.6 million from SGD 1.16 million year-over-year.

Outlook and guidance

• Targeting completion of phase one trial for CTM-N2D in 2026.

• Published preclinical study results in collaboration with MD Anderson Cancer Center in September 2025.

• Applying for GDT trial in Malaysia and exploring international collaborations with income potential.

• Signed ATM agreement to raise up to $4.3 million in August 2025.

• Management expects current resources and proceeds from recent and potential equity offerings to be sufficient for at least the next 12 months.